Identification of clonal skin myeloid cells by next‐generation sequencing in myelodysplasia cutis

Abstract

number 16_136). CPRD collects deidentified patient data from a network of general practitioner practices across the UK. Primary care data are linked to a range of other health-related data to provide a longitudinal, representative UK population health dataset. The data encompass 50 million patients, including 14 million currently registered patients. Additional methods and results are available upon direct request. In our cohort there were 12 057, 17 614 and 80 854 patients in the whole of the UK living with MM, SCC or BCC, respectively. The prevalence of MM was 0Á3%, SCC had a prevalence of 0Á4%, and BCC had the highest prevalence at 1Á8%. Over the 10-year study period, there was a 36% increase in the age-adjusted incidence of MM, a 34% increase in SCC and a 21% increase of BCC. Sex-stratified incidence per 100 000 person years (PYs) was age-adjusted (SEM) for 2004 and then 2014 [for MM, 15Á8 (0Á9) to 26Á4 (1Á0) for men and 22Á4 (1Á1) to 25Á5 (1Á0) for women; for SCC, 48Á2 (1Á4) to 66Á0 (1Á6) for men and 25Á4 (1Á2) to 32Á6 (1Á2) for women; and for BCC, 161Á2 (2Á6) to 201Á1 (2Á7) for men and 124Á0 (2Á5) to 143Á8 (2Á5) for women].

Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series

“…Recently, it has been shown using FISH in four patients and NGS in one patient followed for MDS that cutaneous lesions infiltrated by immature myeloid non-blastic cells were clonally related to the myeloid malignancy, and some authors suggested that they should be classified as myelodysplasia cutis ( 15 , 16 ). Similarly, studying skin biopsies of patients with SS in the setting of MDS/CMML or acute myeloid leukemia, Passet et al found a clonal infiltrate on the biopsies of 4/4 patients with a neutrophilic-SS associated with MDS/CMML ( 14 ).…”

“…Interestingly, a case of NGS identifying a clonal infiltrate in myelodysplasia cutis , consisting in an immature myeloid histiocytoid non-blastic infiltrate in the setting of MDS, was recently reported, as defined by Osio et al. ( 15 , 16 ). Given these preliminary data, we sought to better characterize skin lesions of patients with MDS/CMML using NGS, hypothesizing that a majority of skin lesions could be related to a clonal myeloid infiltrate of the skin and thus share common mutations with the hematological MDS/CMML clone found in blood and marrow.…”

Myelodysplasia cutis as the presenting sign of chronic myelomonocytic leukaemia

“…3 Interestingly, next-generation sequencing studies have shown that the histiocytoid cells of MDC arise directly from the myelodysplastic clone in the bone marrow, suggesting that MDC represents a specific cutaneous localization of MDS. 3,4 It is important to differentiate MDC from leukaemia cutis (LC), as these conditions differ markedly in terms of therapeutic management and prognosis.…”

“…Frequently, MDC overlaps both clinically and pathologically with the histiocytoid variant of Sweet syndrome, which is prevalently observed in patients with chronic myeloid malignancies 3 . Interestingly, next‐generation sequencing studies have shown that the histiocytoid cells of MDC arise directly from the myelodysplastic clone in the bone marrow, suggesting that MDC represents a specific cutaneous localization of MDS 3,4 . It is important to differentiate MDC from leukaemia cutis (LC), as these conditions differ markedly in terms of therapeutic management and prognosis.…”

Corrigendum

“…In the article by Delaleu et al 1 , one of the authors was listed as K. Rathana. It should have been R. Kim.…”